EcoDrugPlus

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSLOCG00000012080
Gene Symbol: NFKB1
3 Cross references
200 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSLOCG00000015206
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSLOCG00000006349
Gene Symbol: NR1H3
1 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSLOCG00000010508
Gene Symbol: NR3C1
3 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSLOCG00000008694
Gene Symbol: NR3C2
3 Cross references
212 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSLOCG00000003690
Gene Symbol: OPRD1
3 Cross references
251 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSLOCG00000005766
Gene Symbol: OPRK1
3 Cross references
262 Possible Orthologues:

Opioid Receptor, Mu 1

Ensembl ID : ENSLOCG00000015439
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSLOCG00000005285
Gene Symbol: OPRL1
3 Cross references
199 Possible Orthologues:

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSLOCG00000014365
Gene Symbol: PAK4
1 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSLOCG00000009481
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSLOCG00000013954
Gene Symbol: PPARG
4 Cross references
406 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).